Mirum Pharmaceuticals, Inc. MIRM Volixibat — Development or regulatory milestones incurred
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:DevelopmentOrRegulatoryMilestonesIncurred.
The official record: Mirum Pharmaceuticals, Inc.’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s volixibat — development or regulatory milestones incurred.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s volixibat — development or regulatory milestones incurred?
- Mirum Pharmaceuticals, Inc. (MIRM) reported volixibat — development or regulatory milestones incurred of $0 in Q4 2025.
- What does volixibat — development or regulatory milestones incurred mean?
- Represents the expenses recognized in the financial statements for clinical development or regulatory milestones that have been achieved for the Volixibat program. Unlike cash payments, this metric focuses on the accounting recognition of liabilities or expenses tied to specific R&D progress. It is a critical measure for understanding the timing and impact of development successes on the company's income statement.